Summary & Overview
HCPCS G0327: Colorectal Cancer Screening, Blood-Based Biomarker
HCPCS Level II code G0327 denotes a blood-based biomarker screening for colorectal cancer, a non-invasive screening option intended to identify individuals who may need follow-up diagnostic evaluation. Nationally, adoption of blood-based colorectal screening has grown as part of efforts to increase screening rates and expand access to alternatives to stool-based tests and colonoscopy. This code matters because it standardizes reporting for payers and providers offering the test in outpatient settings and clinical laboratories.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical purpose, common sites of service, and what to expect in a national payer landscape. The publication also outlines benchmark metrics where available, summarizes recent policy and coverage trends affecting blood-based colorectal screening, and provides clinical context regarding the screening intent and role of biomarker assays within colorectal cancer early-detection strategies.
Data not available in the input for some operational details such as associated taxonomies, typical ICD-10 diagnosis codes, and service line specifics.
Billing Code Overview
HCPCS Level II code G0327 describes a colorectal cancer screening using a blood-based biomarker. This service represents testing of a blood specimen to detect biomarkers associated with colorectal cancer, intended as a screening modality rather than diagnostic or surveillance testing.
-
Service type: Blood-based biomarker screening
-
Typical site of service: Outpatient laboratory or clinic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old average-risk patient presents to a primary care clinic for routine colorectal cancer screening and declines colonoscopy or stool-based testing. The clinician orders a blood-based biomarker screening test billed with G0327 (Colorectal cancer screening; blood-based biomarker). A phlebotomy technician draws blood during the visit and the specimen is sent to a commercial laboratory. The laboratory performs the assay and returns a report indicating a positive or negative biomarker result. If positive, the clinician discusses diagnostic follow-up and refers the patient for colonoscopy. If negative, the clinician documents informed shared decision-making and schedules routine surveillance per screening interval.
Key workflow steps:
-
Patient encounter and informed consent for screening.
-
Order entry for the blood-based biomarker test (
G0327). -
Specimen collection (phlebotomy) and proper labeling.
-
Laboratory processing and result reporting to the ordering provider.
-
Result-based follow-up: positive result → referral for diagnostic colonoscopy; negative result → routine screening interval documentation.
-
Billing submission with appropriate modifier(s) when applicable and linkage to the screening/diagnosis code in the medical record.